Related Experiment Video

Updated: Jun 26, 2026

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

[Arterial hypertension and the kidney]

A Niang1

  • 1Service de Néphrologie, CHU A. le Dantec, BP 6548, Dakar, Senegal. niangabdou@yahoo.com

Dakar Medical
|December 24, 2008
PubMed

Insights

Arterial hypertension, a major cardiovascular risk, requires therapeutic action when blood pressure exceeds 140/90 mmHg. Thiazide diuretics combined with ACE inhibitors or ARBs offer optimal cardioprotection and nephroprotection for patients with renal diseases.

Area of Science:

  • Cardiology and Nephrology
  • Hypertension Research
  • Pharmacology

Context:

  • Arterial hypertension is a leading global cause of cardiovascular mortality.
  • Blood pressure exceeding 140/90 mmHg signifies significant cardiovascular risk requiring intervention.
  • The pressure natriuresis relationship is a key long-term blood pressure regulatory mechanism, often disrupted in hypertension.

Purpose:

  • To review the therapeutic strategies for arterial hypertension, particularly in patients with renal diseases.
  • To highlight the role of thiazide diuretics in antihypertensive regimens.
  • To evaluate the combined efficacy of thiazide diuretics with ACE inhibitors or ARBs for cardioprotection and nephroprotection.

Summary:

  • While diagnostic and monitoring guidelines for hypertension are established, therapeutic strategies remain debated.
  • Lifestyle modifications are foundational, but many patients with renal diseases necessitate combination drug therapy.
  • Thiazide diuretics are recommended as a primary agent, with notable benefits when combined with ACE inhibitors or angiotensin receptor antagonists (ARBs).

Impact:

  • This review emphasizes optimal therapeutic combinations for managing hypertension and its complications.
  • The findings support enhanced cardioprotective and nephroprotective outcomes in hypertensive patients with kidney disease.
  • Provides evidence-based recommendations for clinical practice in hypertension management.

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Assessment of Vascular Function in Patients With Chronic Kidney Disease08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...